EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 522 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR No Clinical Benefit from Nivolumab Plus Ipilimumab Over Nivolumab Alone as... April 14, 2023 ESMO Calls for Cancer to Be at the Core of the... June 10, 2025 FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... March 8, 2024 A Cancer Revolution: What the experts think of the new Science... July 25, 2022 Load more HOT NEWS FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ Opinion: ‘We need to increase testing in primary care’
